Table 2 Clinical characteristics of study participants by group (October 20, 2016 to July 18, 2018)
Characteristics | Same-day group n (%) | > 7 days group n (%) |
|---|---|---|
BMI (N = 987)—Median (IQR)† | 20.1 (18.3–22.3) | 19.6 (17.5–22.0) |
CD4 cell count/mm3 (N = 571)† | ||
< 200 | 58 (34.3) | 218 (54.2) |
200–349 | 31 (18.3) | 86 (21.4) |
≥ 350 | 80 (47.3) | 98 (24.4) |
WHO clinical stage (N = 988)† | ||
Stage I | 323 (74.6) | 241 (43.4) |
Stage II | 71 (16.4) | 134 (24.1) |
Stage III | 35 (8.1) | 141 (25.4) |
Stage IV | 4 (0.9) | 39 (7.0) |
OI at enrollment (N = 988)† | ||
Yes | 37 (8.6) | 142 (25.6) |
No | 396 (91.5) | 413 (74.4) |
CPT within 6-months (N = 988)† * | ||
Yes | 124 (28.6) | 373 (67.2) |
No | 30 (6.9) | 17 (3.1) |
Not eligible | 276 (64.4) | 165 (29.7) |
CPT within 12-months (N = 988)† ** | ||
Yes | 103 (23.8) | 335 (60.4) |
No | 43 (9.9) | 44 (7.9) |
Not eligible | 287 (66.3) | 176 (31.7) |
IPT within 6-months (N = 988)† * | ||
Yes | 273 (63.1) | 213 (38.4) |
No | 142 (32.8) | 275 (49.6) |
Not eligible | 18 (4.2) | 67 (12.1) |
IPT within 12-months (N = 988)† ** | ||
Yes | 269 (62.1) | 259 (46.7) |
No | 139 (32.1) | 229 (41.3) |
Not eligible | 25 (5.8) | 67 (12.1) |
ARV regimen started (N = 988)† | ||
TDF + 3TC + EFV (FDC) | 431 (99.5) | 533 (96.0) |
AZT + 3TC + EFV | 1 (0.2) | 10 (1.8) |
Others | 1 (0.2) | 12 (2.2) |